Skip to content
10-Q/A

Quarterly Report

Regenicin, Inc.

0001662252-22-000017

← back to feed
Filed
Mar 25, 2022 12:00 AM ET
Period of report
Amendment. Amends a previously filed report.
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2021 · Dec 31, 2021 153.48M sh
Operating Cash Flow Q1 2021 · Dec 31, 2021 −$10.63K
Operating Cash Flow Q1 2021 · Dec 31, 2020 −$11.19K
Stockholders Equity restated Q1 2021 · Dec 31, 2021 −$4.29M
Stockholders Equity restated Q1 2021 · Sep 30, 2021 −$4.96M
Stockholders Equity Q1 2021 · Dec 31, 2020 −$4.45M
Stockholders Equity Q1 2021 · Sep 30, 2020 −$4.29M
Current Liabilities Q1 2021 · Dec 31, 2021 $5.12M
Current Liabilities Q1 2021 · Sep 30, 2021 $4.96M
Total Assets Q1 2021 · Dec 31, 2021 $5.83K
Total Assets Q1 2021 · Sep 30, 2021 $4.61K
Sga Expense Q1 2021 · Dec 31, 2021 $146.53K
Sga Expense Q1 2021 · Dec 31, 2020 $150.82K
Net Income Q1 2021 · Dec 31, 2021 −$154.13K
Net Income restated Q1 2021 · Dec 31, 2020 −$159.88K
Operating Income Q1 2021 · Dec 31, 2021 −$146.53K
Operating Income Q1 2021 · Dec 31, 2020 −$150.82K